7 October 2019 -  420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each year from a bundle deal PHARMAC has finalised with a medicine supplier.

The agreement with Roche Products (New Zealand) includes funding three new treatments, as well as widened access to one currently funded treatment.

“These medicines are going to make a real difference to the lives of people who, in some cases, are living with very severe conditions and symptoms,” says Dr Ken Clark, PHARMAC’s acting medical director.

Read PHARMAC press release